Arcelia Arrieta
Research Subjects
Arcelia Arrieta has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Javier Castañeda
Medtronic Bakken Research Center Maastricht The Netherlands
3 shared publications - Isabeau Thijs
Medtronic Diabetes, Medtronic International Trading Sàrl Tolochenaz Switzerland
2 shared publications - Ohad Cohen
Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel
2 shared publications Benedikt Voelker
Medtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland
1 shared publication- David Norman O'Neal
Department of Endocrinology and Diabetes, St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia
1 shared publication - Fiona M. Campbell
Department of Paediatric Diabetes, Leeds Children’s Hospital, Leeds, U.K.
1 shared publication
Latest Publications
- 12 March 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (4) , 1302-1310
Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.
- 12 March 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (4) , 1302-1310
Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.
- Open Access
- 4 February 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (4) , 2242-2250
MiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets
Aims: Large‐scale studies on the effectiveness of automated insulin delivery (AID) systems in older people with type 1 diabetes are still limited. A multinational, retrospective, real‐world study was conducted to examine the performance of the MiniMed™ 780G advanced hybrid closed‐loop system in users with type 1 diabetes aged ≥56 years compared with those aged 16–55 years. Materials and Methods: Data from 35 366 MiniMed™ 780G system users aged 16–55 years and 7415 users aged ≥56 years were included. The main outcome was time in range 70–180 mg/dL (TIR); other continuous glucose monitoring (CGM) metrics were also assessed. Results: Across all users, mean TIR was 77.1% for users aged ≥56 years and 73.1% for those aged 16–55 years (Δ4.0, 95% confidence interval [CI]: 3.8–4.2, p p <0.0001). Across all users, mean time below range 70% without increasing hypoglycaemia risk. Users employing optimal settings showed the best outcomes. The system performed as well as or better than in younger users. These findings support the case that more stringent TIR targets can be achieved safely.
- 4 February 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (4) , 2242-2250
Open AccessMiniMed 780G system performance in older users with type 1 diabetes: Real‐world evidence and the case for stricter glycaemic targets
Aims: Large‐scale studies on the effectiveness of automated insulin delivery (AID) systems in older people with type 1 diabetes are still limited. A multinational, retrospective, real‐world study was conducted to examine the performance of the MiniMed™ 780G advanced hybrid closed‐loop system in users with type 1 diabetes aged ≥56 years compared with those aged 16–55 years. Materials and Methods: Data from 35 366 MiniMed™ 780G system users aged 16–55 years and 7415 users aged ≥56 years were included. The main outcome was time in range 70–180 mg/dL (TIR); other continuous glucose monitoring (CGM) metrics were also assessed. Results: Across all users, mean TIR was 77.1% for users aged ≥56 years and 73.1% for those aged 16–55 years (Δ4.0, 95% confidence interval [CI]: 3.8–4.2, p p <0.0001). Across all users, mean time below range 70% without increasing hypoglycaemia risk. Users employing optimal settings showed the best outcomes. The system performed as well as or better than in younger users. These findings support the case that more stringent TIR targets can be achieved safely.
- Open Access
- 27 May 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (9) , 1100-1108
Use of sensor‐integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real‐world study in the UK
Aims To assess the efficacy of insulin pumps with automated insulin suspension systems in a real‐world setting. Methods We analysed anonymized data uploaded to CareLink™ by people (n=920) with Type 1 diabetes using the MiniMed Paradigm Veo system and the MiniMed 640G system (Medtronic International Trading Sàrl, Tolochanez, Switzerland) with SmartGuard technology, with or without automated insulin suspension enabled, between February 2016 and June 2018. Users with ≥15 days of sensor data and ≥70% sensor‐wear time were classified as sensor‐augmented pump alone, sensor‐integrated pump with low glucose suspend enabled or sensor‐integrated pump with predictive low glucose management enabled. Results The median (25th–75th percentile) system use was 161 (58–348) days. The median time spent with sensor glucose values ≤3 mmol/l was 0.8 (0.3–1.7)% in the sensor‐augmented pump group, 0.3 (0.1–0.7)% in the sensor‐integrated pump with low glucose suspend group, and 0.3 (0.1–0.5)% in the sensor‐integrated pump with predictive low glucose management group. In individuals switching from sensor‐augmented pump to sensor‐integrated pump with low glucose suspend (n=31), there were significant reductions in the monthly rate of hypoglycaemic events P=0.009) and in the percentage of time with glucose values ≤3 mmol/l [sensor‐augmented pump: 0.63% (95% CI 0.34–1.29), sensor‐integrated pump with low glucose suspend: 0.33% (95% CI 0.16–0.64); P=0.001]. The monthly rate of hypoglycaemic events decreased further in individuals (n=139) switching from sensor‐integrated pump with low glucose suspend to sensor‐integrated pump with predictive low glucose management [rate ratio 0.82 (95% CI 0.69–0.98); P<0.0274]. Similar results were seen for events <3.9 mmol/l. There was no difference in median time spent in target glucose range. Conclusion Real‐world UK data show that increasing automation of insulin suspension reduces hypoglycaemia exposure in people with Type 1 diabetes.
- 27 May 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (9) , 1100-1108
Open AccessUse of sensor‐integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real‐world study in the UK
Aims To assess the efficacy of insulin pumps with automated insulin suspension systems in a real‐world setting. Methods We analysed anonymized data uploaded to CareLink™ by people (n=920) with Type 1 diabetes using the MiniMed Paradigm Veo system and the MiniMed 640G system (Medtronic International Trading Sàrl, Tolochanez, Switzerland) with SmartGuard technology, with or without automated insulin suspension enabled, between February 2016 and June 2018. Users with ≥15 days of sensor data and ≥70% sensor‐wear time were classified as sensor‐augmented pump alone, sensor‐integrated pump with low glucose suspend enabled or sensor‐integrated pump with predictive low glucose management enabled. Results The median (25th–75th percentile) system use was 161 (58–348) days. The median time spent with sensor glucose values ≤3 mmol/l was 0.8 (0.3–1.7)% in the sensor‐augmented pump group, 0.3 (0.1–0.7)% in the sensor‐integrated pump with low glucose suspend group, and 0.3 (0.1–0.5)% in the sensor‐integrated pump with predictive low glucose management group. In individuals switching from sensor‐augmented pump to sensor‐integrated pump with low glucose suspend (n=31), there were significant reductions in the monthly rate of hypoglycaemic events P=0.009) and in the percentage of time with glucose values ≤3 mmol/l [sensor‐augmented pump: 0.63% (95% CI 0.34–1.29), sensor‐integrated pump with low glucose suspend: 0.33% (95% CI 0.16–0.64); P=0.001]. The monthly rate of hypoglycaemic events decreased further in individuals (n=139) switching from sensor‐integrated pump with low glucose suspend to sensor‐integrated pump with predictive low glucose management [rate ratio 0.82 (95% CI 0.69–0.98); P<0.0274]. Similar results were seen for events <3.9 mmol/l. There was no difference in median time spent in target glucose range. Conclusion Real‐world UK data show that increasing automation of insulin suspension reduces hypoglycaemia exposure in people with Type 1 diabetes.